www.myrbetriqhcp.com Open in urlscan Pro
40.121.16.193  Public Scan

Form analysis
1 forms found in the DOM

Name: RequestARep — POST /request-a-rep/

<form action="/request-a-rep/" class="left-rhythm-padding" id="RequestARep" method="post" name="RequestARep" onsubmit=" return validateForm(this)" novalidate="novalidate"><input name="__RequestVerificationToken" type="hidden"
    value="aywpDKZp3tOELv_CVzBRhlzlTYD0ieFHDrqp646HRrYS4zwGfoEkS3rW_g3_fIq2TQINEQdJ8jx7s5tMvfo8mzrsb-eUhts5hYuz6nuNK1c1">
  <h4 class="small no-margin">Please select any of the topics below applicable to your interests (optional):</h4>
  <div class="row left-rhythm-padding">
    <div class="col-sm-6">
      <input id="Topic_0__Value" name="Topic[0].Value" type="hidden" value="EFFICACY">
      <input data-fieldname="EFFICACY" data-val="true" data-val-required="The Selected field is required." id="Topic_0__Selected" name="Topic[0].Selected" type="checkbox" value="true"><input name="Topic[0].Selected" type="hidden" value="false">
      <input id="TopicList_0__Text" name="TopicList[0].Text" type="hidden" value="Myrbetriq efficacy information">
      <label for="Topic_0__Selected"> Myrbetriq efficacy information </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_1__Value" name="Topic[1].Value" type="hidden" value="SAFETY">
      <input data-fieldname="SAFETY" data-val="true" data-val-required="The Selected field is required." id="Topic_1__Selected" name="Topic[1].Selected" type="checkbox" value="true"><input name="Topic[1].Selected" type="hidden" value="false">
      <input id="TopicList_1__Text" name="TopicList[1].Text" type="hidden" value="Myrbetriq safety profile">
      <label for="Topic_1__Selected"> Myrbetriq safety profile </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_2__Value" name="Topic[2].Value" type="hidden" value="DOSING">
      <input data-fieldname="DOSING" data-val="true" data-val-required="The Selected field is required." id="Topic_2__Selected" name="Topic[2].Selected" type="checkbox" value="true"><input name="Topic[2].Selected" type="hidden" value="false">
      <input id="TopicList_2__Text" name="TopicList[2].Text" type="hidden" value="Dosing and administration">
      <label for="Topic_2__Selected"> Dosing and administration </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_3__Value" name="Topic[3].Value" type="hidden" value="EDUCATION">
      <input data-fieldname="EDUCATION" data-val="true" data-val-required="The Selected field is required." id="Topic_3__Selected" name="Topic[3].Selected" type="checkbox" value="true"><input name="Topic[3].Selected" type="hidden" value="false">
      <input id="TopicList_3__Text" name="TopicList[3].Text" type="hidden" value="Patient educational brochures">
      <label for="Topic_3__Selected"> Patient educational brochures </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_4__Value" name="Topic[4].Value" type="hidden" value="SAMPLES">
      <input data-fieldname="SAMPLES" data-val="true" data-val-required="The Selected field is required." id="Topic_4__Selected" name="Topic[4].Selected" type="checkbox" value="true"><input name="Topic[4].Selected" type="hidden" value="false">
      <input id="TopicList_4__Text" name="TopicList[4].Text" type="hidden" value="Information about samples">
      <label for="Topic_4__Selected"> Information about samples </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_5__Value" name="Topic[5].Value" type="hidden" value="COMBINATION">
      <input data-fieldname="COMBINATION" data-val="true" data-val-required="The Selected field is required." id="Topic_5__Selected" name="Topic[5].Selected" type="checkbox" value="true"><input name="Topic[5].Selected" type="hidden" value="false">
      <input id="TopicList_5__Text" name="TopicList[5].Text" type="hidden" value="Combination therapy">
      <label for="Topic_5__Selected"> Combination therapy </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_6__Value" name="Topic[6].Value" type="hidden" value="MOMENTUM">
      <input data-fieldname="MOMENTUM" data-val="true" data-val-required="The Selected field is required." id="Topic_6__Selected" name="Topic[6].Selected" type="checkbox" value="true"><input name="Topic[6].Selected" type="hidden" value="false">
      <input id="TopicList_6__Text" name="TopicList[6].Text" type="hidden" value="Information about the &amp;lt;em&amp;gt;Momentum&amp;lt;/em&amp;gt; Program">
      <label for="Topic_6__Selected"> Information about the <em>Momentum</em> Program </label>
    </div>
    <div class="col-sm-6">
      <input id="Topic_7__Value" name="Topic[7].Value" type="hidden" value="OTHER">
      <input data-fieldname="OTHER" data-val="true" data-val-required="The Selected field is required." id="Topic_7__Selected" name="Topic[7].Selected" type="checkbox" value="true"><input name="Topic[7].Selected" type="hidden" value="false">
      <input id="TopicList_7__Text" name="TopicList[7].Text" type="hidden" value="Other*">
      <label for="Topic_7__Selected"> Other* </label>
    </div>
  </div>
  <h4 class="small margin-top-35 is-request-rep">Please Verify Your Information</h4>
  <p class="large no-margin is-request-rep"><em data-gtm-vis-recent-on-screen-844496_225="197" data-gtm-vis-first-on-screen-844496_225="197" data-gtm-vis-total-visible-time-844496_225="100" data-gtm-vis-has-fired-844496_225="1">Please note that
      fields marked with (†) are required.</em></p>
  <div class="row">
    <div class="col-sm-6">
      <label for="FirstName">First Name<i></i></label>
      <input data-val="true" data-val-maxlength="Please enter a valid First Name" data-val-maxlength-max="35" data-val-minlength="Please enter a valid First Name" data-val-minlength-min="2" data-val-regex="Please enter your First Name"
        data-val-regex-pattern="^[a-zA-Z\s]*$" data-val-required="Please enter your First Name" id="FirstName" name="FirstName" onblur="searchHCPs()" type="text" value="">
      <span class="field-validation-valid" data-valmsg-for="FirstName" data-valmsg-replace="true"></span>
    </div>
    <div class="col-sm-6">
      <label for="LastName">Last Name<i></i></label>
      <input data-val="true" data-val-maxlength="Please enter a valid Last Name" data-val-maxlength-max="35" data-val-minlength="Please enter a valid Last Name" data-val-minlength-min="2" data-val-regex="Please enter your Last Name"
        data-val-regex-pattern="^[a-zA-Z\s]*$" data-val-required="Please enter your Last Name" id="LastName" name="LastName" onblur="searchHCPs()" type="text" value="">
      <span class="field-validation-valid" data-valmsg-for="LastName" data-valmsg-replace="true"></span>
    </div>
    <div class="col-sm-6">
      <label for="Profession">Profession Type<i></i></label>
      <select data-val="true" data-val-required="Please select" id="Profession" name="Profession" onchange="searchHCPs()">
        <option value="">Please select</option>
        <option value="MD">Physician (Doctor of Medicine)</option>
        <option value="DO">Physician (Doctor of Osteopathy)</option>
        <option value="PA">Physician Assistant</option>
        <option value="APRN">Nurse Practitioner</option>
        <option value="MD">Pathologist</option>
        <option value="NURSE">Registered Nurse</option>
        <option value="LPN">Licensed Practical Nurse</option>
        <option value="PHAR">Pharmacist</option>
        <option value="PHT">Pharmacy Tech</option>
        <option value="Other">Other</option>
      </select>
      <span class="field-validation-valid" data-valmsg-for="Profession" data-valmsg-replace="true"></span>
    </div>
    <div class="col-sm-6 is-state-select">
      <label for="State" data-gtm-vis-recent-on-screen-844496_227="194" data-gtm-vis-first-on-screen-844496_227="194" data-gtm-vis-total-visible-time-844496_227="100" data-gtm-vis-has-fired-844496_227="1">State<i></i></label>
      <select data-val="true" data-val-required="Please select your State" id="State" name="State" onchange="searchHCPs()">
        <option value="">Please select a state</option>
        <option value="AL">Alabama</option>
        <option value="AK">Alaska</option>
        <option value="AZ">Arizona</option>
        <option value="AR">Arkansas</option>
        <option value="CA">California</option>
        <option value="CO">Colorado</option>
        <option value="CT">Connecticut</option>
        <option value="DE">Delaware</option>
        <option value="DC">District Of Columbia</option>
        <option value="FL">Florida</option>
        <option value="GA">Georgia</option>
        <option value="HI">Hawaii</option>
        <option value="ID">Idaho</option>
        <option value="IL">Illinois</option>
        <option value="IN">Indiana</option>
        <option value="IA">Iowa</option>
        <option value="KS">Kansas</option>
        <option value="KY">Kentucky</option>
        <option value="LA">Louisiana</option>
        <option value="ME">Maine</option>
        <option value="MD">Maryland</option>
        <option value="MA">Massachusetts</option>
        <option value="MI">Michigan</option>
        <option value="MN">Minnesota</option>
        <option value="MS">Mississippi</option>
        <option value="MO">Missouri</option>
        <option value="MT">Montana</option>
        <option value="NE">Nebraska</option>
        <option value="NV">Nevada</option>
        <option value="NH">New Hampshire</option>
        <option value="NJ">New Jersey</option>
        <option value="NM">New Mexico</option>
        <option value="NY">New York</option>
        <option value="NC">North Carolina</option>
        <option value="ND">North Dakota</option>
        <option value="OH">Ohio</option>
        <option value="OK">Oklahoma</option>
        <option value="OR">Oregon</option>
        <option value="PA">Pennsylvania</option>
        <option value="RI">Rhode Island</option>
        <option value="SC">South Carolina</option>
        <option value="SD">South Dakota</option>
        <option value="TN">Tennessee</option>
        <option value="TX">Texas</option>
        <option value="UT">Utah</option>
        <option value="VT">Vermont</option>
        <option value="VA">Virginia</option>
        <option value="WA">Washington</option>
        <option value="WV">West Virginia</option>
        <option value="WI">Wisconsin</option>
        <option value="WY">Wyoming</option>
      </select>
      <span class="field-validation-valid" data-valmsg-for="State" data-valmsg-replace="true"></span>
    </div>
    <div class="col-sm-6">
      <label for="Phone">Phone Number<i></i></label>
      <input data-val="true" data-val-regex="Please enter a valid Office Phone"
        data-val-regex-pattern="^(?:(?:\+?1\s*(?:[.-]\s*)?)?(?:\(\s*([2-9]\d{2})\s*\)|([2-9]\d{2}))\s*(?:[.-]\s*)?)([2-9]\d{2})\s*(?:[.-]\s*)?([0-9]{4})(?:\s*(?:#|x\.?|ext\.?|extension)\s*(\d+))?$"
        data-val-required="Please enter a valid Phone Number" id="Phone" name="Phone" type="text" value="">
      <span class="field-validation-valid" data-valmsg-for="Phone" data-valmsg-replace="true"></span>
    </div>
    <div class="col-sm-6">
      <label for="Email">Email Address<i></i></label>
      <input data-val="true" data-val-maxlength="Please enter a valid Email Address" data-val-maxlength-max="254" data-val-regex="Please enter a valid Email Address"
        data-val-regex-pattern="^(([^<>()[\]\.,;:\s@\&quot;]+(\.[^<>()[\]\.,;:\s@\&quot;]+)*)|(\&quot;.+\&quot;))@(([^<>()[\]\.,;:\s@\&quot;]+\.)+[^<>()[\]\.,;:\s@\&quot;]{2,})$" data-val-required="Please enter a valid Email Address" id="Email"
        name="Email" type="email" value="">
      <span class="field-validation-valid" data-valmsg-for="Email" data-valmsg-replace="true"></span>
    </div>
  </div>
  <div id="dinamychcps"></div>
  <input id="ID" name="ID" type="hidden" value=""> <input button="" type="submit" value="Submit" class="m-btn-yellow larger-margin">
  <p>*Any questions about off-label use of Myrbetriq should be directed to:</p>
  <p class="reduced-margin"><strong>Medical Communications</strong></p>
  <p class="no-margin">Phone: <a href="tel: 1 (800) 727-7003" class="disable-mobile-highlight">1 (800) 727-7003</a></p>
  <p class="no-margin">Fax: <a href="tel: 1 (877) 829-7942" class="disable-mobile-highlight">1 (877) 829-7942</a></p>
  <p class="no-margin">Website: <a href="https://www.astellasanswers.com" target="_blank" rel="noopener" class="is-underlined "><strong>www.astellasanswers.com</strong></a></p>
</form>

Text Content

 * Full Prescribing Information
 * Important Safety Information
 * Urology Resources
 * Patient Site
 * Request a Rep

Menu
 * Home
 * Mechanism
   of Action
 * Efficacy
   * Study Design
   * Efficacy Results
   * Adults ≥65 (PILLAR):
     Study Design
   * Adults ≥65 (PILLAR):
     Efficacy Results
 * Safety
   * Safety Results
   * Adults ≥65 (PILLAR):
     Safety Results
 * Dosing &
   Administration
   * Dosing
   * Drug-to-Drug Interactions
 * Combination
   Treatment
   * MOA
   * Combination Therapy
   * Add-on Therapy
   * Safety
   * Dosing
 * Support
   * Patient Support
   * Savings & Support
   * Physician Support

 * Full Prescribing Information
 * Important Safety Information
 * Urology Resources
 * Patient Site
 * Request a Rep

Request Samples
Study Design
Efficacy Results
Adults ≥65 (PILLAR): Study Design
Adults ≥65 (PILLAR): Efficacy Results
Safety Results
Adults ≥65 (PILLAR): Safety Results
Dosing
Drug-to-Drug Interactions
MOA
Combination Therapy
Add-on Therapy
Safety
Dosing
Patient Resources
Savings & Support
Physician Resources
Safety and efficacy
Medicare Part D coverage


REQUEST A VISIT FROM A SALES REP


LEARN MORE ABOUT MYRBETRIQ, COMBINATION THERAPY, OR THE MOMENTUM PROGRAM

PLEASE SELECT ANY OF THE TOPICS BELOW APPLICABLE TO YOUR INTERESTS (OPTIONAL):

Myrbetriq efficacy information
Myrbetriq safety profile
Dosing and administration
Patient educational brochures
Information about samples
Combination therapy
Information about the Momentum Program
Other*

PLEASE VERIFY YOUR INFORMATION

Please note that fields marked with (†) are required.

First Name
Last Name
Profession Type Please select Physician (Doctor of Medicine) Physician (Doctor
of Osteopathy) Physician Assistant Nurse Practitioner Pathologist Registered
Nurse Licensed Practical Nurse Pharmacist Pharmacy Tech Other
State Please select a state Alabama Alaska Arizona Arkansas California Colorado
Connecticut Delaware District Of Columbia Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan
Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey
New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon
Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah
Vermont Virginia Washington West Virginia Wisconsin Wyoming
Phone Number
Email Address


*Any questions about off-label use of Myrbetriq should be directed to:

Medical Communications

Phone: 1 (800) 727-7003

Fax: 1 (877) 829-7942

Website: www.astellasanswers.com

Important Safety Information,
Indications and Usage

Show more Show less
Show less

INDICATIONS AND USAGE

MYRBETRIQ® (mirabegron extended-release tablets), either alone or in combination
with the muscarinic antagonist solifenacin succinate, is indicated for the
treatment of overactive bladder (OAB) in adult patients with symptoms of urge
urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

Myrbetriq® (mirabegron extended-release tablets) is contraindicated in patients
with known hypersensitivity reactions to mirabegron or any inactive ingredients
of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase
blood pressure in adults. Periodic blood pressure determinations are
recommended, especially in hypertensive patients. MYRBETRIQ is not recommended
for use in patients with severe uncontrolled hypertension (defined as systolic
blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening
of pre-existing hypertension was reported infrequently in patients taking
MYRBETRIQ.

MYRBETRIQ® (mirabegron extended-release tablets) is contraindicated in patients
with known hypersensitivity reactions to mirabegron or any inactive ingredients
of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase
blood pressure in adults. Periodic blood pressure determinations are
recommended, especially in hypertensive patients. MYRBETRIQ is not recommended
for use in patients with severe uncontrolled hypertension (defined as systolic
blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening
of pre-existing hypertension was reported infrequently in patients taking
MYRBETRIQ.

In patients taking MYRBETRIQ, urinary retention has been reported in patients
with bladder outlet obstruction (BOO) and in patients taking muscarinic
antagonist medications for the treatment of OAB. A controlled clinical safety
study in patients with BOO did not demonstrate increased urinary retention in
patients treated with mirabegron; however, MYRBETRIQ should still be
administered with caution to patients with clinically significant BOO. For
example, monitor these patients for signs and symptoms of urinary retention.
MYRBETRIQ should also be administered with caution to patients taking muscarinic
antagonist medications for the treatment of OAB, including solifenacin
succinate.

Angioedema of the face, lips, tongue and/or larynx has been reported with
MYRBETRIQ. In some cases, angioedema occurred after the first dose. Cases have
been reported to occur hours after the first dose or after multiple doses.
Angioedema, associated with upper airway swelling, may be life threatening. If
involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue
MYRBETRIQ and initiate appropriate therapy and/or measures necessary to ensure a
patent airway.

Since MYRBETRIQ is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6
substrates is increased when co‐administered with MYRBETRIQ. Therefore,
appropriate monitoring and dose adjustment may be necessary, especially with
narrow therapeutic index drugs metabolized by CYP2D6.

In clinical trials, the most commonly reported adverse reactions in adults (> 2%
and > placebo) for MYRBETRIQ 25mg and 50mg versus placebo, respectively, were
hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%),
urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs.
3.0%).

In clinical trials, the most commonly reported adverse reactions in adults (> 2%
and > placebo and > comparator) for MYRBETRIQ in combination with solifenacin
succinate 25mg + 5mg and 50mg + 5mg versus MYRBETRIQ 25mg, MYRBETRIQ 50mg,
solifenacin succinate 5mg, and placebo, respectively, were dry mouth (9.3%, 7.2%
vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%,
3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and
tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%).

In postmarketing experience with mirabegron, the following events have also
occurred: atrial fibrillation, nausea, diarrhea, and dizziness.

Please refer to prescribing information for solifenacin succinate when
prescribing MYRBETRIQ in combination with solifenacin succinate.

Please click here for complete Prescribing Information for Myrbetriq®
(mirabegron extended-release tablets)

 * Home
 * Mechanism
   of Action
 * Efficacy
   * Study Design
   * Efficacy Results
   * Adults ≥65 (PILLAR):
     Study Design
   * Adults ≥65 (PILLAR):
     Efficacy Results
 * Safety
   * Safety Results
   * Adults ≥65 (PILLAR):
     Safety Results
 * Dosing &
   Administration
   * Dosing
   * Drug-to-Drug Interactions
 * Combination
   Treatment
   * MOA
   * Combination Therapy
   * Add-on Therapy
   * Safety
   * Dosing
 * Support
   * Patient Support
   * Savings & Support
   * Physician Support

To learn more about patient assistance programs for Myrbetriq, please call
Astellas Pharma Support SolutionsSM at 1‑800‑477‑6472 or go to
www.astellaspharmasupportsolutions.com.

Myrbetriq, VESIcare, Astellas, and the flying star logo are registered
trademarks of Astellas Pharma, Inc. All other trademarks or registered
trademarks are the property of their respective owners.

This site is intended for US Healthcare Professionals only.
©2021 Astellas Pharma US, Inc.

055-0370-PM

 * Privacy Policy
 * Legal Disclaimer
 * Request a Rep
 * Contact Us
 * Medical Information

The information contained on this site is intended for
healthcare professionals in the United States only.
It is not intended for the general public.

I AM a US healthcare professional I am NOT a US healthcare professional
×


YOU ARE NOW LEAVING MYRBETRIQHCP.COM

You are now leaving myrbetriqhcp.com. The website you are linking to is neither
owned nor controlled by Astellas. Astellas is not responsible for the content or
services on the site.

Continue to Twitter.

Continue Cancel

This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a
registered trademark of Astellas Pharma Inc.


YOU ARE NOW LEAVING MYRBETRIQHCP.COM

By clicking “Continue,” you will leave MyrbetriqHCP.com and enter
astellasmedinfo.com. The information contained on Astellas Medical Information
is intended for U.S. healthcare professionals only.

Continue Cancel

This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a
registered trademark of Astellas Pharma Inc.


ELIGIBILITY RESTRICTIONS, TERMS & CONDITIONS

TO THE PATIENT: This offer is not valid for patients whose prescription claims
are reimbursed, in whole or in part, by any state or federal government program,
including, but not limited to, Medicaid, Medicare, Medigap, Department of
Defense (DoD), Veterans Affairs (VA), TRICARE, CHAMPUS, Puerto Rico Government
Health Insurance, or any State Patient or Pharmaceutical Assistance Program.
This offer is void where prohibited by law. Certain rules and restrictions
apply.

Note: If you use a mail-order pharmacy, please contact your pharmacy provider to
ensure that this offer will be accepted. If the mail-order pharmacy will not
process your voucher, please call 1‑866‑666‑8244 (Monday-Friday, 8 a.m.-8 p.m.
ET, excluding holidays) and request to speak to an agent. An agent will mail a
Direct Member Reimbursement (DMR) form to you. The form should be completed and
returned to the address on the form, along with your pharmacy receipt. If you
are eligible, you will receive your benefit in the mail. You can also visit
www.patientrebateonline.com to obtain a DMR form.

TO THE PHARMACIST: By redeeming this coupon, I certify that (i) I have received
this coupon from an eligible patient, (ii) I have dispensed the products
indicated, (iii) I have not submitted, and will not submit, a claim for
reimbursement to Part D of Medicare, Medicaid, or any similar federal or state
program, including a state pharmaceutical assistance program, and (iv) I will
otherwise comply with the terms hereof.

I further certify that my participation in this program is consistent with all
applicable state laws and any obligations, contractual or otherwise, that I have
as a pharmacy provider. Please submit the amount of co‑pay authorized by the
patient's primary insurance as a secondary transaction to McKesson. For pharmacy
processing assistance or questions, please call the Help Desk at 1-866-666-8244.

HOURS OF OPERATION: Monday-Friday, 8 a.m.-8 p.m. ET, excluding holidays.

Astellas reserves the right to rescind, revoke, or amend this offer without
notice. This program is not insurance.



Important Safety Information,
Indications and Usage

Show more Show less
Show less

INDICATIONS AND USAGE

MYRBETRIQ® (mirabegron extended-release tablets), either alone or in combination
with the muscarinic antagonist solifenacin succinate, is indicated for the
treatment of overactive bladder (OAB) in adult patients with symptoms of urge
urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

Myrbetriq® (mirabegron extended-release tablets) is contraindicated in patients
with known hypersensitivity reactions to mirabegron or any inactive ingredients
of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase
blood pressure in adults. Periodic blood pressure determinations are
recommended, especially in hypertensive patients. MYRBETRIQ is not recommended
for use in patients with severe uncontrolled hypertension (defined as systolic
blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening
of pre-existing hypertension was reported infrequently in patients taking
MYRBETRIQ.

MYRBETRIQ® (mirabegron extended-release tablets) is contraindicated in patients
with known hypersensitivity reactions to mirabegron or any inactive ingredients
of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase
blood pressure in adults. Periodic blood pressure determinations are
recommended, especially in hypertensive patients. MYRBETRIQ is not recommended
for use in patients with severe uncontrolled hypertension (defined as systolic
blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening
of pre-existing hypertension was reported infrequently in patients taking
MYRBETRIQ.

In patients taking MYRBETRIQ, urinary retention has been reported in patients
with bladder outlet obstruction (BOO) and in patients taking muscarinic
antagonist medications for the treatment of OAB. A controlled clinical safety
study in patients with BOO did not demonstrate increased urinary retention in
patients treated with mirabegron; however, MYRBETRIQ should still be
administered with caution to patients with clinically significant BOO. For
example, monitor these patients for signs and symptoms of urinary retention.
MYRBETRIQ should also be administered with caution to patients taking muscarinic
antagonist medications for the treatment of OAB, including solifenacin
succinate.

Angioedema of the face, lips, tongue and/or larynx has been reported with
MYRBETRIQ. In some cases, angioedema occurred after the first dose. Cases have
been reported to occur hours after the first dose or after multiple doses.
Angioedema, associated with upper airway swelling, may be life threatening. If
involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue
MYRBETRIQ and initiate appropriate therapy and/or measures necessary to ensure a
patent airway.

Since MYRBETRIQ is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6
substrates is increased when co‐administered with MYRBETRIQ. Therefore,
appropriate monitoring and dose adjustment may be necessary, especially with
narrow therapeutic index drugs metabolized by CYP2D6.

In clinical trials, the most commonly reported adverse reactions in adults (> 2%
and > placebo) for MYRBETRIQ 25mg and 50mg versus placebo, respectively, were
hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%),
urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs.
3.0%).

In clinical trials, the most commonly reported adverse reactions in adults (> 2%
and > placebo and > comparator) for MYRBETRIQ in combination with solifenacin
succinate 25mg + 5mg and 50mg + 5mg versus MYRBETRIQ 25mg, MYRBETRIQ 50mg,
solifenacin succinate 5mg, and placebo, respectively, were dry mouth (9.3%, 7.2%
vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%,
3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and
tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%).

In postmarketing experience with mirabegron, the following events have also
occurred: atrial fibrillation, nausea, diarrhea, and dizziness.

Please refer to prescribing information for solifenacin succinate when
prescribing MYRBETRIQ in combination with solifenacin succinate.

Please click here for complete Prescribing Information for Myrbetriq®
(mirabegron extended-release tablets)